U.S. patent application number 15/658046 was filed with the patent office on 2017-11-09 for stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles.
The applicant listed for this patent is Intarcia Therapeutics Inc.. Invention is credited to Stephen A. Berry, Houdin Dehnad, Pamela J. Fereira, Anna Muchnik.
Application Number | 20170319662 15/658046 |
Document ID | / |
Family ID | 26817087 |
Filed Date | 2017-11-09 |
United States Patent
Application |
20170319662 |
Kind Code |
A1 |
Berry; Stephen A. ; et
al. |
November 9, 2017 |
STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS
UTILIZING SUCH VEHICLES
Abstract
This invention relates to stable non-aqueous single phase
viscous vehicles and to formulations utilizing such vehicles. The
formulations comprise at least one beneficial agent uniformly
suspended in the vehicle. The formulation is capable of being
stored at temperatures ranging from cold to body temperature for
long periods of time. The formulations are capable of being
uniformly delivered from drug delivery systems at an exit shear
rate of between about 1 to 1.times.10.sup.7 reciprocal second.
Inventors: |
Berry; Stephen A.;
(Hollister, CA) ; Fereira; Pamela J.; (Redwood
City, CA) ; Dehnad; Houdin; (El Granada, CA) ;
Muchnik; Anna; (Belmont, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Intarcia Therapeutics Inc. |
Boston |
MA |
US |
|
|
Family ID: |
26817087 |
Appl. No.: |
15/658046 |
Filed: |
July 24, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15408344 |
Jan 17, 2017 |
|
|
|
15658046 |
|
|
|
|
14632701 |
Feb 26, 2015 |
|
|
|
15408344 |
|
|
|
|
13219262 |
Aug 26, 2011 |
8992961 |
|
|
14632701 |
|
|
|
|
12077117 |
Mar 17, 2008 |
8048438 |
|
|
13219262 |
|
|
|
|
10319277 |
Dec 12, 2002 |
|
|
|
12077117 |
|
|
|
|
09497422 |
Feb 3, 2000 |
7258869 |
|
|
10319277 |
|
|
|
|
60119170 |
Feb 8, 1999 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/0024 20130101;
A61K 9/0004 20130101; A61K 47/44 20130101; A61K 38/27 20130101;
A61K 47/32 20130101; A61M 5/14224 20130101; A61K 47/26 20130101;
A61M 2205/04 20130101; Y10S 514/937 20130101; A61K 47/14 20130101;
Y10T 29/49826 20150115; A61M 5/145 20130101; A61K 47/10 20130101;
A61K 47/12 20130101; A61M 5/14276 20130101 |
International
Class: |
A61K 38/27 20060101
A61K038/27; A61K 47/32 20060101 A61K047/32; A61K 47/26 20060101
A61K047/26; A61K 47/14 20060101 A61K047/14; A61K 47/12 20060101
A61K047/12; A61K 47/10 20060101 A61K047/10; A61K 9/00 20060101
A61K009/00; A61K 47/44 20060101 A61K047/44; A61K 9/00 20060101
A61K009/00 |
Claims
1. A non-aqueous formulation comprising a beneficial agent,
polymer, and sugar; suspended in a non-aqueous single-phase
vehicle, wherein: the beneficial agent is glucagon-like peptide-1
(GLP-1) or a peptide analog thereof; the polymer comprises at least
one of polylactic acid or polylacticpolyglycolic acid; and the
non-aqueous single-phase vehicle comprises sesame oil, peanut oil
or Miglyol.RTM. triglycerides.
2. The non-aqueous formulation of claim 1, wherein the beneficial
agent is GLP-1.
3. The non-aqueous formulation of claim 1, wherein the beneficial
agent is a peptide analog of GLP-1.
4. The non-aqueous formulation of claim 3, wherein the polymer
comprises polylactic acid.
5. The non-aqueous formulation of claim 3, wherein the polymer
comprises polylacticpolyglycolic acid.
6. The non-aqueous formulation of claim 5, wherein the non-aqueous
single-phase vehicle comprises sesame oil.
7. The non-aqueous formulation of claim 5, wherein the non-aqueous
single-phase vehicle comprises peanut oil.
8. The non-aqueous formulation of claim 5, wherein the non-aqueous
single-phase vehicle comprises Miglyol.RTM. triglycerides.
9. The non-aqueous formulation of claim 8, wherein the sugar
comprises sucrose.
10. The non-aqueous formulation of claim 1, consisting of a
beneficial agent, polymer, and sugar; suspended in a non-aqueous
single-phase vehicle, wherein the beneficial agent is glucagon-like
peptide-1 (GLP-1) or a peptide analog thereof; the polymer is
polylacticpolyglycolic acid; and the non-aqueous single-phase
vehicle is Miglyol.RTM. triglycerides; and the sugar is
sucrose.
11. A non-aqueous formulation comprising a beneficial agent and
polymer; suspended in a non-aqueous single-phase vehicle, wherein:
the beneficial agent is glucagon-like peptide-1 (GLP-1) or a
peptide analog thereof; the polymer comprises at least one of
polylactic acid or polylacticpolyglycolic acid; and the non-aqueous
single-phase vehicle comprises sesame oil, peanut oil or
Miglyol.RTM. triglycerides.
12. The non-aqueous formulation of claim 11, consisting of a
beneficial agent and polymer; suspended in a non-aqueous
single-phase vehicle, wherein the beneficial agent is glucagon-like
peptide-1 (GLP-1) or a peptide analog thereof; the polymer is
polylacticpolyglycolic acid; and the non-aqueous single-phase
vehicle is Miglyol.RTM. triglycerides.
13. An implantable drug delivery device, comprising a reservoir
containing the non-aqueous formulation of claim 1; said implantable
drug delivery device further comprising an osmotic engine, a
piston, and a rate controlling membrane.
Description
RELATED APPLICATIONS
[0001] The present application claims a priority benefit as a
continuation (CON) of U.S. non-provisional patent application Ser.
No. 15/408,344, entitled "Stable Non-aqueous Single Phase Viscous
Vehicles and Formulations Utilizing Such Vehicles," filed on Jan.
17, 2017, and currently pending, the content of which is
incorporated herein by reference in its entirety.
[0002] U.S. non-provisional application Ser. No. 15/408,344 claims
a priority benefit as a continuation (CON) of U.S. non-provisional
patent application Ser. No. 14/632,701, entitled "Stable
Non-aqueous Single Phase Viscous Vehicles and Formulations
Utilizing Such Vehicles," filed on Feb. 26, 2015, now abandoned,
the content of which is incorporated herein by reference in its
entirety.
[0003] U.S. non-provisional application Ser. No. 14/632,701 claims
a priority benefit as a continuation (CON) of U.S. non-provisional
patent application Ser. No. 13/219,262, entitled "Stable
Non-aqueous Single Phase Viscous Vehicles and Formulations
Utilizing Such Vehicles," filed on Aug. 26, 2011, and issued as
U.S. Pat. No. 8,992,961 on Mar. 31, 2015, the content of which is
incorporated herein by reference in its entirety.
[0004] U.S. non-provisional application Ser. No. 13/219,262 claims
a priority benefit as a continuation (CON) of U.S. non-provisional
patent application Ser. No. 12/077,117, entitled "Stable
Non-aqueous Single Phase Viscous Vehicles and Formulations
Utilizing Such Vehicles," filed on Mar. 17, 2008, and issued as
U.S. Pat. No. 8,048,438 on Nov. 1, 2011, the content of which is
incorporated herein by reference in its entirety.
[0005] U.S. non-provisional application Ser. No. 12/077,117 claims
a priority benefit as a continuation (CON) of U.S. non-provisional
patent application Ser. No. 10/319,277, entitled "Stable
Non-aqueous Single Phase Viscous Vehicles and Formulations
Utilizing Such Vehicles," filed on Dec. 12, 2002, now abandoned,
the content of which is incorporated herein by reference in its
entirety.
[0006] U.S. non-provisional application Ser. No. 10/319,277 claims
a priority benefit as a continuation (CON) of U.S. non-provisional
patent application Ser. No. 09/497,422, entitled "Stable
Non-aqueous Single Phase Viscous Vehicles and Formulations
Utilizing Such Vehicles," filed on Feb. 3, 2000, and issued as U.S.
Pat. No. 7,258,869 on Aug. 21, 2007, the content of which is
incorporated herein by reference in its entirety.
[0007] U.S. non-provisional application Ser. No. 09/497,422 claims
a priority benefit to U.S. provisional patent application Ser. No.
60/119,170, entitled "Stable Non-aqueous Single Phase Gels
Exhibiting Viscous Fluid Characteristics and Formulations Utilizing
Such Gels," filed on Feb. 8, 1999, the content of which is
incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0008] This invention relates to stable non-aqueous single phase
biocompatible viscous vehicles capable of suspending beneficial
agents and uniformly dispensing said agents at low flow rates and
more particularly to stable uniformly mixed formulations of
beneficial agents in stable non- aqueous single phase biocompatible
viscous vehicles.
REFERENCES
[0009] The following references are referred to by numbers in
brackets ([ ]) at the relevant portion of the specification. [0010]
1. Wang, et al., J. Parenteral Sci. Tech, 42: S4-S26 (1988). [0011]
2. Desai, et al., J. Am. Chem. Soc., 116: 9420-9422 (1994). [0012]
3. Chang, et al., Pharm. Tech., 80-84 (January 1996). [0013] 4.
Manning, et al., Pharm. Res., 6: 903-918 (1989). [0014] 5. Hageman,
Drug Dev. Ind. Pharm, 14: 2047-2070 (1988). [0015] 6. Bell, et al.,
Biopolymers, 35: 201-209 (1995). [0016] 7. Zhang, et al., Pharm.
Res. 12: 1447-1452 (1995). [0017] 8. PCT published application
98/00158 [0018] 9. PCT published application 98/16250 [0019] 10.
Knepp, et al., Pharm. Res. 1.sctn.(7) 1090-1095 (1998). [0020] 11.
PCT published application 98/00157 [0021] 12. PCT published
application 98/00152 [0022] 13. U.S. Pat. No. 5,540,912 [0023] 14.
U.S. Pat. No. 5,571,525 [0024] 15. U.S. Pat. No. 5,512,293 [0025]
16. PCT published application 96/40049 [0026] 17. Yu, et al., J.
Pharm. Sci., 85: 396-401 (1996). [0027] 18. Mitchell, U.S. Pat. No.
5,411,951 (1995). [0028] 19. Brooks, et al., U.S. Pat. No.
5,352,662 (1994) [0029] 20. Geller, L., U.S. Pat. No. 3,869,549
(1975). [0030] 21. Larsen, et al., PCT Publication No. WO95/34285
(1995). [0031] 22. Knepp, et al., J. Pharm. Sci. Tech, 50: 163-171
(1996). [0032] 23. U.S. Pat. No. 5,614,221 [0033] 24. U.S. Pat. No.
4,594,108 [0034] 25. U.S. Pat. No. 5,300,302 [0035] 26. U.S. Pat.
No. 4,588,614 [0036] 27. U.S. Pat. No. 4,310,516 [0037] 28. U.S.
Pat. No. 5,635,213 [0038] 29. EP 379,147
BACKGROUND OF THE INVENTION
[0039] Peptides, polypeptides, proteins and other proteinaceous
substances (e.g., viruses, antibodies) collectively referred to
herein as proteins, have great utility as pharmaceuticals in the
prevention, treatment and diagnosis of disease. Proteins are
naturally active in aqueous environments, thus the preferred
formulations of proteins have been in aqueous solutions. However,
proteins are only marginally stable in aqueous solutions. Thus,
protein pharmaceuticals often have short shelf-lives under ambient
conditions or require refrigeration. Further, many proteins have
only limited solubility in aqueous solutions. Even when they are
soluble at high concentrations, they are prone to aggregation and
precipitation.
[0040] Because proteins can easily degrade, the standard method for
delivering such compounds has been daily injections. Proteins can
degrade via a number of mechanisms, including deamidations of
asparagine and glutamine; oxidation of methionine and, to a lesser
degree, tryptophan, tyrosine and histidine; hydrolysis of peptide
bonds; disulfide interchange; and racemization of chiral amino acid
residues [1-7]. Water is a reactant in nearly all of these
degradation pathways. Further, water acts as a plasticizer, which
30 facilitates unfolding and irreversible aggregation of proteins.
Since water is a participant in almost all protein degradation
pathways, reduction of aqueous protein solution to a dry powder
provides an alternative formulation methodology to enhance the
stability of protein pharmaceuticals.
[0041] One approach to stabilizing proteins is to dry them using
various techniques, including freeze-drying, spray-drying,
lyophilization, and desiccation. Dried proteins are stored as dry
powders until their use is required.
[0042] A serious drawback to drying of proteins is that often one
would like to use proteins in some sort of flowable form.
Parenteral injection and the use of drug delivery devices for
sustained delivery of drug are two examples of the applications
where one would like to use proteins in a flowable form. For
injection, dried proteins must be reconstituted, adding additional
steps which are time-consuming and where contamination may occur,
and exposing the protein to potentially destabilizing conditions
[7]. For drug delivery devices the protein formulations must be
stable for extended periods of time at body temperature and
maintain their flowability for the expected life of the device.
[0043] Solution formulations of proteins/peptides in non-aqueous
polar aprotic solvents such as DMSO and DMF have been shown to be
stable at elevated temperatures for long periods of time [8].
However, such solvent based formulations will not be useable for
all proteins since many proteins have low solubility in these
solvents. The lower the solubility of the protein in the
formulation, the more solvent would have to be used for delivery of
a specific amount of protein. Low concentration solutions may be
useful for injections, but may not be useful for long term delivery
at low flow rates.
[0044] Proteins have been formulated for delivery using
perfluorodecalin [9, 10], methoxyflurane [9], high concentrations
in water [11], polyethylene glycol [12], PLGA [13, 14],
ethylenevinylacetate/polyvinylpyrridone mixtures [15],
PEG400/povidone [16]. However, these formulations were not shown to
retain a uniform suspension of protein in viscous vehicle over long
periods of time.
[0045] Many biologically active compounds degrade over time in
aqueous solution. Carriers in which proteins do not dissolve but
rather are suspended, can often offer improved chemical stability.
Furthermore, it can be beneficial to suspend the beneficial agent
in a carrier when the agent exhibits low solubility in the desired
vehicle. However, suspensions can have poor physical stability due
to settling and agglomeration of the suspended beneficial agent.
The problems with non-aqueous carriers tend to be exacerbated as
the concentration of the active compound is increased.
[0046] Dispersing powdered proteins or peptides in lipid vehicles
to yield parenteral sustained release formulations has been
investigated [17-21]. The vehicles used were either various
vegetable (sesame, soy, peanut, etc.) or synthetic oils (e.g.,
Miglyol) gelled with aluminum fatty acid esters such as aluminum
stearates (mono-, di- or tri-), or with a polyglycerol ester.
Although theoretically these vehicles might preclude solution
denaturation and protect the drug from aqueous chemical
degradation, the vehicles themselves are unstable at higher
temperatures. The storage of liquid vegetable oils at body
temperatures results in the formation of reactive species such as
free fatty acids and peroxides (a process which is accelerated by
the presence of traces of various metal ions such as copper or iron
which can leach from some implantable devices). These peroxides not
only adversely affect protein stability [22] but would be toxic
when delivered directly to, for example, the central nervous system
of a human or animal.
[0047] The sustained delivery of drugs has many advantages. Use of
implantable devices assures patient compliance, since the delivery
device is tamperproof. With one insertion of a device, rather than
daily injections, there is reduced site irritation, fewer
occupational hazards for practitioners improved cost effectiveness
through decreased costs of equipment for repeated injections,
reduced hazards of waste disposal, and enhanced efficacy through
controlled release as compared with depot injection. The use of
implantable devices for sustained delivery of a wide variety of
drugs or other beneficial agents is well known in the art. Typical
devices are described, for example, in U.S. Pat. Nos. 5,034,229;
5,057,318; 5,110,596; and 5,782,396. The disclosure of each of
these patents is incorporated herein by reference.
[0048] For drug delivering implants, dosing durations of up to one
year are not unusual. Beneficial agents which have low therapeutic
delivery rates are prime candidates for use in implants. When the
device is implanted or stored, settling of the beneficial agent in
a liquid formulation can occur. This heterogeneity can adversely
affect the concentration of the beneficial agent dispensed.
Compounding this problem is the size of the implanted beneficial
agent reservoir. Implant reservoirs are generally on the order of
25-250 .mu.l, but can be up to 25 ml.
[0049] Viscous formulations have been prepared using two separate
components to be mixed with drug at use [23], thickening agents
added to aqueous compositions [24], gelling agents added to aqueous
drug solutions [25], porous textile sheet material [26], thickening
agents with oleaginous material [27], viscous aqueous carrier for
limited solubility drug [28], and extrudable elastic gels [29].
However, these formulations are mixed at use, contain aqueous
components, use sheet matrices, or are delivered topically, orally,
or intraduodenally.
[0050] Stability of formulations can be enhanced by freeze-drying,
lyophilizing or spray-drying the active ingredient. The process of
drying the active ingredient includes further advantages such as
compounds which are relatively unstable in aqueous solution can be
processed and filled into dosage containers, dried without elevated
temperatures, and then stored in the dry state in which there are
relatively few stability problems. Pharmaceutical formulations,
particularly parenteral products, should be sterilized after being
sealed in the final container and within as short a time as
possible after the filling and sealing have been completed. (See,
for example Remington, Pharmaceutical Sciences, 15th ed. (1975)).
Examples of sterilization techniques include thermal or dry-heat,
aseptic, and ionized radiation. Combinations of these sterilization
procedures may also be used to produce a sterile product.
[0051] There is a need to be able to deliver protein compositions
to the body which are stable at body temperatures over extended
periods of time to enable long term delivery of the protein. There
is a need to be able to deliver concentrations of proteins that are
efficacious. There is a need for a novel non-aqueous formulation
capable of homogeneously suspending proteins and dispensing such
agents at body temperatures and low flow rates over extended
periods of time.
SUMMARY OF THE INVENTION
[0052] The present invention provides stable single phase
non-aqueous biocompatible viscous vehicles capable of forming
uniform suspensions with proteins. The components of the viscous
vehicle comprise at least two of polymer, surfactant, and solvent.
The ratios of the components will vary depending on the molecular
weight of the components and the desired viscosity of the final
vehicle. Presently preferred component ratios are: polymer, about
5% to about 60%; solvent, about 30% to about 50%; and surfactant,
about 5% to about 20%.
[0053] The present invention also provides stable formulations in
which beneficial agents are uniformly suspended in stable single
phase nonaqueous biocompatible viscous vehicles. In particular, the
beneficial agents are formulated in the viscous vehicles at
concentrations of at least about 0.1%, depending upon the potency
of the beneficial agent. These stable formulations may be stored at
the temperature appropriate for the beneficial agent, ranging from
cold, to body temperature (about 37.degree. C.) for long periods of
time (1 month to 1 year or more). In a preferred embodiment the
formulation comprises about 0.1 to 50% (w/w) of beneficial agent,
depending on the potency of the beneficial agent, the duration of
treatment, and the rate of release for the drug delivery
system.
[0054] These formulations are especially useful in implantable
delivery devices for long term delivery (e.g., 1 to 12 months or
longer) of beneficial agent at body temperature, preferably about
37.degree. C. Thus, the present invention also provides for the
delivery of said proteins to the body overextended period of time
to enable long term delivery of the protein at low flow rates of
about 0.3 to 100 .mu.l/day, preferably about 0.3 to 4 .mu.l/day for
about a 6 month delivery period and preferably 5 to 8 .mu.l/day for
about a 3 month delivery period.
[0055] In another aspect, the invention provides methods for
preparing stable non-aqueous biocompatible formulations of a
beneficial agent in a single phase viscous vehicle. Preferred
formulations comprise about 0.1 to 50% (w/w) beneficial agent
depending on the potency of the beneficial agent, the duration of
treatment, and the rate of release from the delivery system. In yet
a further aspect, the invention provides methods for treating a
subject suffering from a condition which may be alleviated by
administration of a beneficial agent, said methods comprising
administering to said subject an effective amount of a stable
non-aqueous formulation comprising at least one beneficial agent
uniformly suspended in a single phase viscous vehicle.
[0056] A further aspect of the invention is that non-aqueous single
phase viscous vehicles containing beneficial agents are chemically
and physically stable over a broad temperature range for long
periods of time. The beneficial agents in the viscous vehicles are
also chemically and physically stable over a broad temperature
range for long periods of time. Thus, these formulations are
advantageous in that they may be shipped and stored at temperatures
below, at, or above room temperature for long period of time. They
are also suitable for use in implantable delivery devices in which
the formulation must be stable at body temperature for extended
periods of time.
[0057] The formulations of the present invention also remain stable
when delivered from implantable drug delivery systems. The
beneficial agents have been shown to exhibit zero order release
rates when delivered from implantable drug delivery systems at very
low flow rates over extended periods of time.
BRIEF DESCRIPTION OF THE DRAWINGS
[0058] FIG. 1 shows the stability of hGH formulations of the
present invention as determined at 37.degree. C. by reverse phase
HPLC.
[0059] FIG. 2 shows the stability of hGH formulations of the
present invention as determined at 37.degree. C. by size exclusion
chromatography.
[0060] FIG. 3 shows the average release rate (.mu.l/day) of 10%
(w/w) spray-dried lysozyme in formulations of the present
invention.
[0061] FIG. 4 shows the average release rate (.mu.l/day) of 10%
(w/w) spray-dried hGH in a glycerol monolaurate/lauryl
lactate/polyvinylpyrrolidone vehicle.
[0062] FIG. 5 shows the average release rate (.mu.g/day) of 10%
lysozyme in a lauryl alcohol/polyvinylpyrrolidone vehicle.
[0063] FIG. 6 shows the average release rate ((.mu.g/day) of 25%
lysozyme in a glycerol monolaurate/lauryl
lactate/polyvinylpyrrolidone vehicle.
[0064] FIG. 7 shows the average release rate ((.mu.g/day) of 33%
lysozyme in a glycerol monolaurate/lauryl
lactate/polyvinylpyrrolidone vehicle.
[0065] FIG. 8 shows the average release rate ((.mu.g/day) of 45%
lysozyme in a glycerol monolaurate/lauryl
lactate/polyvinylpyrrolidone vehicle.
[0066] FIG. 9 and FIG. 10 are partial cross-sectional vies of two
embodiments of the delivery device of the invention.
[0067] FIG. 11 is an enlarged cross-sectional view of the
back-diffusion regulating outlet of FIG. 9.
DETAILED DESCRIPTION OF THE INVENTION
[0068] The present invention is drawn to the unexpected discovery
that uniformly suspending beneficial agents in non-aqueous single
phase biocompatible viscous vehicles results in stable formulations
which can be delivered at body temperature over an extended period
of time at low flow rates. Previously known formulations of
beneficial agents which are buffered aqueous or non-aqueous
solutions which may or may not contain excipients do not provide
formulations which can be uniformly dispensed at body temperatures
at low flow rates over an extended period of time without
exhibiting unacceptable amounts of aggregation or degradation of
the formulation. The presently claimed formulations stabilize
beneficial agents and can be stored at the temperature appropriate
for the beneficial agent The temperatures can range from cold (not
exceeding 8.degree. C.) to body temperature (about 37.degree. C.)
for long periods of time. These formulations are especially useful
in implantable delivery devices for long term delivery (e.g., 1 to
12 months or longer) of drug at low flow rates and at body
temperature, preferably about 37.degree. C.
[0069] Standard beneficial agent formulations consist of dilute
aqueous or non-aqueous solutions or suspensions. Drug stability is
usually achieved by varying one or more of the following: pH,
buffer type, ionic strength, excipients (EDTA, ascorbic acid, etc.)
For these formulations, degradation pathways requiring water
(hydrolysis, deamidation, racemization) cannot be fully stabilized.
In the present invention, beneficial agents formulated in
non-aqueous biocompatible single phase viscous vehicles containing
for example, polyvinylpyrrolidone, vinyl acetate, and/or
polyoxyethylenepolyoxypropylene block copolymers were shown to be
chemically and physically stable. The viscosity of the formulation
will depend upon a number of criteria, including the beneficial
agent potency and concentration, and the process by which the
formulation is prepared. The viscosity of the formulation can be
chosen so that the desired amount of beneficial agent is delivered
over the desired period of time.
[0070] The invention also consists of non-aqueous single phase
biocompatible viscous vehicles capable of uniformly suspending
beneficial agents and formulations containing at least one
beneficial agent uniformly suspended in said viscous vehicle. The
invention also consists of formulations containing at least one
beneficial agent uniformly suspended in a non-aqueous single phase
biocompatible viscous vehicle, which formulations are stable for an
extended period of time at body temperatures, and capable of
delivering said beneficial agents uniformly at low flow rates. The
discovery consists of the realization that stable non-aqueous
viscous vehicles improve the stability of beneficial agents in a
wide range of formulation conditions including concentration,
elevated temperatures and duration of stable formulation, thus
making possible the delivery of beneficial agents in long term
implantable devices that would not otherwise be feasible.
Definitions
[0071] As used herein, the following terms have the following
meanings:
[0072] The term "chemical stability" means that an acceptable
percentage of degradation products produced by chemical pathways
such as oxidation, deamidation, or hydrolysis is formed. In
particular, a formulation is considered chemically stable if no
more than about 35% breakdown products are formed after 2 months at
37.degree. C.
[0073] The term "physical stability" means that an acceptable
percentage of aggregates (e.g., dimers, trimers and larger forms)
are formed by the beneficial agent. For the formulation (viscous
vehicle and beneficial agent) this term means that the formulation
retains stability, flowability, and the ability to uniformly
dispense the beneficial agent. In particular, a formulation is
considered physically stable if no more than about 15% aggregates
are formed after two months at 37.degree. C.
[0074] The term "stable formulation" means that at least about 65%
chemically and physically stable beneficial agent remains after two
months at 37.degree. C. (or equivalent conditions at an elevated
temperature). Particularly preferred formulations are those which
retain at least about 80% chemically and physically stable
beneficial agent under these conditions. Especially preferred
stable formulations are those which do not exhibit degradation
after sterilizing irradiation (e.g., gamma, beta or electron
beam).
[0075] The term "beneficial agent" means peptides, proteins,
nucleotides, hormones, viruses, antibodies, etc. that comprise
polymers of amino acid or nucleic acid residues. These beneficial
agents are generally degradable in water and generally stable as a
dry powder at elevated temperatures. Synthetically produced,
naturally derived or recombinantly produced moieties are included
in this term. The term also includes lipoproteins and post
translationally modified forms, e.g., glycosylated proteins.
Analogs, derivatives, agonists, antagonists and pharmaceutically
acceptable salts of any of these are included in this term. The
term also includes proteins and/or protein substances which have
0-amino acids, modified, derivatized or non-naturally occurring
amino acids in the 0- or L- configuration and/or peptomimetic units
as part of their structure. The term protein will be used in the
present invention. The term also means that the beneficial agent is
present in the solid state, e.g., powder or crystalline.
[0076] The term "excipient" means a more or less inert substance in
a formulation that is added as a diluent or vehicle or to give form
or consistency. Excipients are distinguished from solvents such as
ETOH, which are used to dissolve drugs in formulations. Excipients
include non-ionic surfactants such as polysorbates, which are used
to solubilize drugs in formulations; preservatives such as benzyl
alcohols or methyl or propyl parabens, which are used to prevent or
inhibit microbial growth; chelating agents; flavoring agents; and
other pharmaceutically acceptable formulation aides.
[0077] The term "viscous vehicle" means a vehicle with a viscosity
in the range of about 1,000 to 10,000,000 poise. The term includes
Newtonian and non-Newtonian materials. Preferred are vehicles with
a viscosity of about 10,000 to 250,000 poise. The formulations of
this invention can uniformly expel beneficial agents suspended in
the viscous vehicle from implantable drug delivery devices. The
formulations exhibit a shear rate at the exit of said devices of 1
to 1.times.10.sup.-7 reciprocal second, preferably an exit shear
rate of 1.times.10.sup.-2 to 1.times.10.sup.-5 reciprocal
second.
[0078] The term "single phase" means a solid, semi-solid, or liquid
homogeneous system that is both physically and chemically uniform
throughout as determined by differential scanning calorimetry
(DSC). The DSC scan should show one peak indicative of a single
phase.
[0079] The term "biocompatible" means a property or characteristic
of a viscous vehicle to disintegrate or break down, over a
prolonged period of time, in response to the biological environment
in the patient, by one or more physical or chemical degradative
processes, for example by enzymatic action, oxidation or reduction,
hydrolysis (proteolysis), displacement, e.g. ion exchange, or
dissolution by solubilization, emulsion or micelle formation, and
which material is then absorbed by the body and surrounding tissue,
or otherwise dissipated thereby.
[0080] The term "polymer" includes polyesters such as PLA
(polylactic acid) [having an inherent viscosity in the range of
about 0.5 to 2.0 i.v.] and PLGA (polylacticpolyglycolic acid)
[having an inherent viscosity in the range of about 0.5 to 2.0
i.v.], pyrrolidones such as polyvinylpyrrolidone (having a
molecular weight range of about 2,000 to 1,000,000), esters or
ethers of unsaturated alcohols such as vinyl acetate, and
polyoxyethylenepolyoxypropylene block copolymers (exhibiting a high
viscosity at 37.degree. C.) such as Pluronic 105. Currently
preferred polymer is polyvinylpyrrolidone.
[0081] The term "solvent" includes carboxylic acid esters such as
lauryl lactate, polyhydric alcohols such as glycerin, polymers of
polyhydric alcohols such as polyethylene glycol (having a molecular
weight of about 200 to 600), fatty acids such as oleic acid and
octanoic acid, oils such as castor oil, propylene carbonate, lauryl
alcohol, or esters of polyhydric alcohols such as triacetin
acetate. Currently preferred is lauryl lactate.
[0082] The term "surfactant" includes esters of polyhydric alcohols
such as glycerol monolaurate, ethoxylated castor oil, polysorbates,
esters or ethers of saturated alcohols such as myristyl lactate
(Ceraphyl 50), and polyoxyethylenepolyoxypropylene block copolymers
such as Pluronic. Currently preferred are gylcerol monolaurate and
polysorbates.
[0083] The term "antioxidant" means a pharmaceutically acceptable
aid for stabilization of the beneficial agent against degradation
such as oxidation. Antioxidants include, but are not limited to,
tocopherol (vitamin E), ascorbic acid, ascorbyl palm itate,
butylated hydroxyanisole, butylated hydroxytoluene, and propyl
gallate. A preferred antioxidant depends on solubility and the
efficiency of the antioxidant for protecting against degradation or
chemical change of the beneficial agent in the preferred vehicle.
Currently preferred isascorbyl palmitate.
Preparation of Formulations
[0084] The present invention is drawn to stable non-aqueous single
phase biocompatible viscous vehicles capable of suspending
beneficial agents and uniformly dispensing said beneficial agents
at body temperatures at low flow rates over an extended period of
time. The present invention is also directed to formulations
containing beneficial agents uniformly suspended in said single
phase biocompatible viscous vehicles which are stable for prolonged
periods of time at body temperatures.
[0085] Examples of beneficial agents that may be formulated using
the present invention include those peptides or proteins that have
biological activity or that may be used to treat a disease or other
pathological condition. They include, but are not limited to,
adrenocorticotropic hormone, angiotensin I and 11, atrial
natriuretic peptide, bombesin, bradykinin, calcitonin, cerebellin,
dynorphin N, alpha and beta endorphin, endothelin, enkephalin,
epidermal growth factor, fertirelin, follicular gonadotropin
releasing peptide, galanin, glucagon, GLP-1, gonadorelin,
gonadotropin, goserelin, growth hormone releasing peptide,
histrelin, human growth hormone, insulin, interferons, leuprolide,
LHRH, motilin, nafarerlin, neurotensin, oxytocin, relaxin,
somatostatin, substance P, tumor necrosis factor, triptorelin,
vasopressin, growth hormone, nerve growth factor, blood clotting
factors, ribozymes, and antisense oligonucleotides. Analogs,
derivatives, antagonists agonists and pharmaceutically acceptable
salts of the above may also be used.
[0086] The beneficial agents useful in the formulations and methods
of the present invention can be used in the form of a salt,
preferably a pharmaceutically acceptable salt. Useful salts are
known to those of skill in the art and include salts with inorganic
acids, organic acids, inorganic bases, or organic bases.
[0087] Beneficial agents that are not readily soluble in
non-aqueous solvents are preferred for use in the present
invention. One of skill in the art can easily determine which
compounds will be useful on the basis of their solubility. The
amount of beneficial agent may vary depending on the potency of the
compound, the condition to be treated, the solubility of the
compound, the expected dose and the duration of administration.
(See, for example, Gilman, et. al, The Pharmacological Basis of
Therapeutics, 7th ed. (1990) and Remington, Pharmacological
Sciences, 18th ed. (1990), the disclosures of which are
incorporated herein by reference.)
[0088] It has been unexpectedly found that using a stable
non-aqueous single phase biocompatible viscous vehicle increases
the stability of the beneficial agent. For example, as seen in
FIGS. 1 and 2, human growth hormone (hGH) was found to be stable at
37.degree. C. over 12 weeks in formulations of
polyvinylpyrrolidone/PEG; Pluronic; and glycerol monolaurate/lauryl
lactate/polyvinylpyrrolidone. FIG. 1 shows stability results using
reverse phase HPLC. FIG. 2 shows stability results using size
exclusion chromatography.
[0089] Generally, stable non-aqueous single phase biocompatible
viscous vehicles may be prepared by combining the dry (low moisture
content) ingredients in a dry box or under other dry conditions and
blending them at elevated temperature, preferably about 40 to about
70.degree. C., to allow them to liquefy. The liquid vehicle is
allowed to cool to room temperature. Differential scanning
calorimetry was used to verify that the vehicle was single phase.
The final moisture content of the viscous vehicle was <2%.
[0090] Generally, the stable formulations of the present invention
may be prepared by combining the vehicle and beneficial agent under
dry conditions and blending them under vacuum at elevated
temperature, preferably about 40 to about 70.degree. C., to
disperse the beneficial agent uniformly throughout the vehicle. The
formulation is allowed to cool to room temperature.
[0091] It has been found that drying the beneficial agent prior to
formulation enhances the stability of the formulation.
[0092] It has also been found that adding antioxidants, such as
tocopherol, ascorbic acid, ascorbyl palm itate, butylated
hydroxyanisole, butylated hydroxytoluene, and propyl gallate
reduces the formation of degradation products (e.g., unstable
chemical intermediates) during sterilization.
Methodology
[0093] We have found that stable non-aqueous beneficial agent
formulations utilizing viscous vehicles may be prepared by
combining the ingredients for the viscous vehicle under dry
conditions and blending them at elevated temperature to allow them
to liquefy and form a single phase. Once a single phase viscous
vehicle is formed, the vehicle is allowed to cool to room
temperature. Beneficial agent is added with mixing at elevated
temperature under vacuum to uniformly disperse it in the viscous
vehicle.
[0094] We have tested these beneficial agent formulations, for
example formulations of hGH, for stability by subjecting them to
accelerated aging tests. Results show that these formulations
remained stable over extended periods of time. We have tested
beneficial agent formulations, for example human growth hormone and
lysozyme, for stability by suspending them in a variety of
non-aqueous single phase viscous vehicles prepared according to the
present invention, then subjecting them to accelerated aging at
elevated temperatures. The stability of the formulations was
measured. Results of these studies demonstrate that these
formulations were stable at conditions that approximate or exceed
storage for one year at 37.degree. C.
[0095] We have also tested beneficial agent formulations prepared
as described herein for stability after 2.5 megarads gamma
irradiation. Results show that these formulations remained
chemically and physically stable after such irradiation.
Methods
[0096] The following methods were used to perform the studies in
the Examples that follow. [0097] 1. Preparing Protein powders
[0098] Human Growth Hormone (obtained for example, from BresaGen
Limited, Adelaide, Australia)
[0099] The active agent was reconstituted in deionized water. The
solution containing the active agent was buffer exchanged using an
Amicon Diaflo.RTM. Ultrafiltration membrane (molecular weight
cut-off 10,000).
[0100] The diafiltrated active agent solution was spray dried using
a Yamato mini-spray dryer. Powder was collected in a collection
vessel through a cyclone trap. All handling of the spray dried
powder took place in a dry box evacuated with nitrogen. The
generated powder was analyzed for particle size and distribution,
moisture content, protein content and stability by size exclusion
and reverse-phase chromatography.
[0101] It is known that the conformation of some proteins can be
stabilized by the addition of a sugar (such as sucrose or mannitol)
or a polyol (such as ethylene glycol, glycerol, glucose, and
dextran.) [0102] 2. Preparation of Viscous Vehicles
[0103] We have found that stable single phase biocompatible viscous
vehicles may be prepared by combining the ingredients and blending
them at elevated temperatures to allow them to liquefy and form a
single phase. A differential scanning calorimetry scan showed one
peak, indicative of a single phase. The mixing was completed under
vacuum to remove trapped air bubbles produced from the powders. The
mixer was a dual helix blade mixer (D.I.T.) which runs at a speed
around 40 rpm. Higher speeds can be used but are not required.
[0104] If a three component viscous vehicle is prepared, the
solvent portion of the vehicle was added to the heated bowl of the
mixer first, followed by the surfactant. The polymer was added
last, and the ingredients were mixed until a solution (single
phase) resulted. Vacuum was applied during mixing to remove air
bubbles. The solution was dispensed from the bowl while at elevated
temperature, and allowed to cool to room temperature. On cooling
the vehicle exhibited increased viscosity. Two and single component
gels were made using the same process. [0105] 3. Preparation of
beneficial agent formulations
[0106] To prepare the formulation, the single phase viscous vehicle
was heated and then blended under vacuum with a weighed amount of
beneficial agent. The beneficial agent and the single phase viscous
vehicle were blended in the same manner as the vehicle was
prepared, using a dual helix blade mixer (or other similar mixer).
Mixing speed was between 40 and 120 rpm for approximately 15
minutes or until a uniform dispersion was attained. The resulting
mixture was removed from the mixer, sealed in a dry container, and
allowed to cool to room temperature. [0107] 4. Preparation of
reservoirs
[0108] FIG. 9 shows one embodiment of the device according to the
invention. In FIG. 9 a fluid-imbibing system 10 is shown that
comprises an impermeable reservoir 12. The reservoir 12 is divided
into two chambers by a piston 16. The first chamber 18 is adapted
to contain an active agent and the second chamber 20 is adapted to
contain a fluid-imbibing agent. A back-diffusion regulating outlet
22 is inserted into the open end of the first compartment 18 and a
water-swellable semipermeable plug 24 is inserted into the open end
of the second chamber 20. In FIG. 9, the back-diffusion regulating
outlet 22 is shown as a male threaded member in a mating
relationship with the smooth interior surface of the reservoir 12
thereby forming therebetween helical flow path 34. The pitch (x),
the amplitude (y), and the cross-sectional area and shape of the
helical path 34 formed between the mating surfaces of the
back-diffusion regulating outlet 22 and the reservoir 12 as shown
in FIG. 11 are factors that affect both the efficiency of path 34
preventing back-diffusion of external fluid into the formulation in
chamber 18 and the back pressure in the device. The geometry of
outlet 22 prevents water diffusion into the reservoir. In general,
it is desired that these characteristics be selected so that the
length of the helical flow path 34 and the velocity of flow of
active agent therethrough is sufficient to prevent back-diffusion
of external fluid through the flow path 34 without significantly
increasing the back pressure, so that, following start-up, the
release rate of the active agent is governed by the osmotic pumping
rate.
[0109] FIG. 10 is a second embodiment of the device of the
invention with a reservoir 12, piston 16 and plug 26. In this
embodiment, the flow path 36 is formed between a threaded
back-diffusion regulating outlet 40 and threads 38 formed on the
interior surface of the reservoir 12. The amplitudes of the
threaded portions of the back-diffusion regulating outlet 40 and
reservoir 12 are different so that a flow path 36 is formed between
the reservoir 12 and the back-diffusion regulating outlet 40. The
water-swellable semipermeable plugs 24 and 26 shown in FIGS. 9 and
10 respectively are inserted into the reservoir such that the
reservoir wall concentrically surrounds and protects the plug.
[0110] In FIG. 9, the top portion 50 of the plug 24 is exposed to
the environment of use and may form a flanged end cap portion 56
overlaying the end of reservoir 12. The semipermeable plug 24 is
resiliently engaged with the interior surface of the reservoir 12
and in FIG. 9 is shown to have ridges 60 that serve to frictionally
engage the semipermeable plug 24 with the interior of reservoir 12.
In addition, the ridges 60 serve to produce redundant
circumferential seals that function before the semipermeable plug
24 expands due to hydration. The clearance between ridges 60 and
the interior surface of the reservoir 12 prevents hydration
swelling from exerting stresses on the reservoir 12 that can result
in tensile failure of the reservoir 12 or compression or shear
failure of the plug 24.
[0111] FIG. 10 shows a second embodiment of the semipermeable plug
26 where the plug is injection molded into the top portion of the
reservoir arid where the top of the semipermeable plug 26 is flush
with the top 62 of the reservoir 12. In this embodiment, the
diameter of the plug is substantially less than the diameter of the
reservoir 12. In both embodiments the plugs 24 and 26 will swell
upon exposure to the fluid in body cavity forming an even tighter
seal with the reservoir 12.
[0112] An example of assembly of a delivery device is as follows.
The piston and inner diameter of the reservoir are lightly
lubricated with silicon medical fluid. The piston 16 is inserted
into the open end of chamber 20. Two osmotic engine tablets (40 mg
each) are then inserted on top of piston 16. After insertion, the
osmotic engine is flush with the end of the reservoir. The membrane
plug 24 is inserted by lining up the plug with the reservoir and
pushing gently until the plug is fully engaged in the reservoir.
Active agent is loaded into a syringe which is then used to fill
chamber 18 from its open end by injecting the material into the
open tube until the formulation is .about.3 mm from the end. The
filled reservoir is centrifuged (outlet end "up") to remove any air
bubbles that are trapped in the formulation during filling. The
outlet 22 is screwed into the open end of the reservoir until
completely engaged. As the outlet is screwed in, excess formulation
exits out of the orifice ensuring a uniform fill.
[0113] The reservoirs of implantable drug delivery devices (as
disclosed in U.S. patent application Ser. No. 08/595,761,
incorporated herein by reference) were filled with the appropriate
hGH formulation. The formulation was filled into titanium
reservoirs with a polymer plug blocking each end. The filled
reservoir was then sealed in a polyfoil bag and placed in a
stability testing oven.
[0114] It should be noted that the formulations in the reservoirs
of these devices are completely isolated from the outside
environment. [0115] 5. Reverse Phase-HPLC (RP-HPLC)
[0116] All stability samples of hGH were assayed for protein
content and chemical stability by reverse phase chromatography
(RP-HPLC). Analyses were performed on a Hewlett Packard HP-1090
system with a refrigerated autosampler (4.degree. C.). The
chromatographic conditions used are listed below.
TABLE-US-00001 TABLE 1 RP-HPLC Chromatographic Conditions
Description Parameter Column J. T. Baker-C18, 4.6 .times. 250 mm
Flow Rate 1.0 ml/min Detection 214 nm Mobile Phase A: 0.1% TFA in
water B: 0.1% TFA in acetonitrile time % A % B Gradient 0 65 35 5
50 50 45 35 65 50 30 70 55 65 35
[0117] An hGH reference standard solution was prepared and its
protein content calculated from the absorbance measurement at 280
nm. Three dilutions of this solution, representing 80%, 100%, and
120% of the expected concentration of hGH in the samples were run
in duplicate at the beginning- and the end of each run and used to
calculate total protein content of the samples. [0118] 6. Size
Exclusion Chromatography (SEC)
[0119] All stability samples of hGH were assayed for protein
content and high molecular weight degradation products by size
exclusion chromatography. Analyses were performed on a Hewlett
Packard HP-1090 system with a refrigerated autosampler (4.degree.
C.). The chromatographic conditions used are listed below
TABLE-US-00002 TABLE 2 SEC Chromatographic Conditions Description
Parameter Column TSK-2000SWXL Flow Rate 0.5 ml/min Detection 214 nm
Mobile Phase 25 mM sodium phosphate, 100 mM sodium chloride, pH
7.0
[0120] A hGH reference standard solution was prepared and its
protein content calculated from the absorbance measurement at 280
nm. Three dilutions of this solution, representing 80%, 100%, and
120% of the expected concentration of hGH in the samples were run
in duplicate at the beginning and the end of each run and used to
calculate total protein content of the samples. The amount of high
molecular weight degradation products was calculated by area
normalization.
[0121] The following examples are offered to illustrate this
invention and are not meant to be construed in any way as limiting
the scope of this invention.
EXAMPLE 1
Preparation of Non-Aqueous Single Phase Viscous Vehicles
[0122] The non-aqueous single phase viscous vehicles can be
prepared as follows and shown in the below table [0123] A. Glycerol
monolaurate (Danisco Ingredients, New Century, Kans.) (25 g) was
dissolved in lauryl lactate (ISP Van Dyk Inc., Belleville, N.J.)
(35 g) at 65.degree. C. Polyvinylpyrrolidone C30 (BASF, Mount
Olive, N.J.) (40 g) was added and the mixture blended at about 40
rpm in a dual helix blade mixer (D.I.T.) until a single phase was
achieved. Trapped air bubbles were removed by applying vacuum to
the mixing chamber. The single phase vehicle was dispensed from the
mixer, and allowed to cool to room temperature. [0124] B. Glycerol
monolaurate (Danisco Ingredients, New Century, Kans.) (25 g) was
dissolved in lauryl lactate (ISP Van Dyk Inc., Belleville, N.J.)
(35 g) at 65.degree. C. Polyvinylpyrrolidone C17 (BASF, Mount
Olive, N.J.) (40 g) was added and the mixture blended at about 40
rpm in a dual helix blade mixer (D.I.T.) until a single phase was
achieved. Trapped air bubbles were removed by applying vacuum to
the mixing chamber. The single phase vehicle was dispensed from the
mixer, and allowed to cool to room temperature. [0125] C.
Polyvinylpyrrolidone C30 (BASF, Mount Olive, N.J.) (50 g) was
dissolved in polyethylene glycol 400 (Union Carbide) (50 g) at
approximately 65.degree. C. until a single phase solution was
formed. The single phase vehicle was dispensed from the mixer, and
allowed to cool to room temperature. [0126] D. Polyvinylpyrrolidone
C17 (BASF, Mount Olive, N.J.) (50 g) was dissolved in polyethylene
glycol 400 (Union Carbide) (50 g) at approximately 65.degree. C.
until a single phase solution was formed. The single phase vehicle
was dispensed from the mixer, and allowed to cool to room
temperature. [0127] E. Polyvinylpyrrolidone C17 (BASF, Mount Olive,
N.J.) (50 g) was dissolved in castor oil (Spectrum, Gardena,
Calif.) (50 g) at approximately 65.degree. C. until a single phase
solution was formed. The single phase vehicle was dispensed from
the mixer, and allowed to cool to room temperature. [0128] F.
Polyvinylpyrrolidone C17 (BASF, Mount Olive, N.J.) (50 g) was
dissolved in octanoic acid (Spectrum, Gardena, Calif.) at
approximately 65.degree. C. until a single phase solution was
formed. The single phase vehicle was dispensed from the mixer, and
allowed to cool to room temperature. [0129] G. Polyvinylpyrrolidone
C17 (BASF, Mount Olive, N.J.) (50 g) was dissolved in oleic acid
(Spectrum, Gardena, Calif.) at approximately 65.degree. C. until a
single phase solution was formed. The single phase vehicle was
dispensed from the mixer, and allowed to cool to room temperature.
[0130] H. Polyvinylpyrrolidone C17 (BASF, Mount Olive, N.J.) (35%)
was dissolved in glycerin (Baker, N.J.) (65%) at approximately
65.degree. C. until a single phase solution was formed. The single
phase vehicle was dispensed from the mixer, and allowed to cool to
room temperature. [0131] I. Cremophor EL (ethoxylated castor oil)
(BASF, Mount Olive, N.J.) (5%) was dissolved in castor oil
(Spectrum, Gardena, Calif.) (70%), and polyvinylpyrrolidone C17
(BASF, Mount Olive, N.J.) (25%) was added and dissolved by mixing
at approximately 40 rpm to form a single phase vehicle. The single
phase vehicle was dispensed from the mixer, and allowed to cool to
room temperature. [0132] J. Pluronic 105 (BASF, Mount Olive, N.J.)
was heated to approximately 65.degree. C. with mixing until melted.
The single phase vehicle was dispensed from the mixer, and allowed
to cool to room temperature.
TABLE-US-00003 [0132] TABLE 3 Component Ratios Component Viscosity
at Low Polymer Surfactant Solvent Ratio Shear Rate (Poise) PVP GML
LL 53:5:42 25,000 PVP GML LL 55:10:35 50,000 PVP GML LL 50:15:35
7,000 PVP -- LL 60:40 PVP Ceraphyl 50 LA 60:10:30 PVP -- oleic acid
50:50 30,000 PVP -- octanoic acid 55:45 7,000 PVP polysorbate 80 --
50:50 PVP -- PEG 400 50:50 PVP castor oil -- 50:50 PVP Pluronic 105
-- 100 1,000,000 PVP -- glycerin 50:50 5,000 Wherein: GML =
glycerol monolaurate LL = lauryl lactate PVP = polyvinylpyrrolidine
C30 LA = lauryl alcohol PEG = polyethyleneglycol 400
EXAMPLE 2
Preparation of hGH
A. Preparation by Spray Drying
[0133] Lyophilized hGH (BresaGen Limited, Adelaide, Australia) was
reconstituted in 150 ml of deionized water. This stock solution
contained 1050 mg of hGH. Buffer exchange was accomplished using an
Amicon Diaflo.RTM. Ultrafiltration membrane (molecular weight
cut-off 10,000). The ultrafiltration cell was connected to an
auxiliary reservoir containing 5 mM phosphate buffer (pH 7). The
cell's fluid volume, as well as the hGH concentration, remained
constant as excipients were replaced by phosphate buffer.
[0134] The diafiltrated protein solution (protein concentration in
the solution approximately 2%) was spray dried using a Yamato
mini-spray dryer. Settings on the spray dryer were as follows:
aspiration pressure constantly adjusted to 1.3 kgf/cm.sup.2, inlet
temperature 120.degree. C., solution flow rate 2.5 (approximately 3
ml/min). Powder was collected in a collection vessel through a
cyclone trap. All handling of the spray dried powder took place in
a dry box evacuated with nitrogen (% RH: 1-4%). The water content
of the suspending vehicles is shown in the below table.
TABLE-US-00004 TABLE 4 WATER CONTENT OF SUSPENDING VEHICLES Water
Content of Vehicle at T 0 Water Content of Vehicle Vehicle % w/w in
12 wks. At 37.degree. C. % w/w Pluronic 105 0.25 0.4 GML/LL/PVP 1.5
1.3 PVP/PEG 2.0 2.0 Wherein: GML = glycerol monolaurate LL = lauryl
lactate PVP = polyvinylpyrrolidine C30 PEG = polyethyleneglycol
400
EXAMPLE 3
Preparation of hGH Formulation
[0135] A portion of the single phase viscous vehicle was weighed (9
g) and was heated to 60.degree. C. hGH (BresaGen Limited, Adelaide,
Australia) (1 g) was added to the vehicle and mixed for 15 minutes.
The mixing was completed under vacuum to remove air bubbles added
from the powder.
[0136] Approximately 10 mg of the spray-dried hGH powder were
weighed out (content of hGH in the powder was recalculated based on
the determined water and salt content) and mixed with 100 .mu.l of
the vehicle at 55-65.degree. C. (3 samples per each vehicle).
Special care was taken while mixing powder in the suspending
vehicle to achieve maximum particle uniform dispersion in the
vehicle. All steps were done in a dry box.
[0137] The resulting suspension was dissolved with 10 ml of release
rate buffer and analyzed by size exclusion and reverse-phase
chromatography. Spray dried hGH powder was used as a control.
TABLE-US-00005 TABLE 5 STABILITY OF hGH SUSPENSIONS AT 37.degree.
C. AS MEASURED BY SIZE EXCLUSION CHROMATOGRAPHY Spray-dried
PVP/PEG400 GML/LL/PVP Pluronic 105 Time Powder-80.degree. C.
suspension suspension suspension Weeks % LS % LS % LS % LS 0 96
.+-. 1 88 .+-. 6 92 .+-. 2 87 .+-. 7 1 99 .+-. 8 81 .+-. 2 94 .+-.
3 93 .+-. 3 2 99 .+-. 3 83 .+-. 1 97 .+-. 1 94 .+-. 1 3 97 .+-. 1
84 .+-. 2 95 .+-. 2 95 .+-. 3 4 95 .+-. 2 82 .+-. 8 94 .+-. 4 93
.+-. 5 7 95 .+-. 4 76 .+-. 3 93 .+-. 4 88 .+-. 2 12 97 .+-. 4 79
.+-. 3 97 .+-. 1 95 .+-. 6
Each data point represents the mean.+-.relative standard deviation
of three individual samples taken from three separate vials.
TABLE-US-00006 TABLE 6 STABILITY OF hGH SUSPENSIONS at 37.degree.
C. AS MEASURED BY REVERSE PHASE CHROMATOGRAPHY Spray-dried
PVP/PEG400 GML/LL/PVP Pluronic 105 Time Powder-80.degree. C.
suspension suspension suspension Weeks % LS % LS % LS % LS 0 104
.+-. 1 99 .+-. 3 99 .+-. 2 89 .+-. 7 1 104 .+-. 8 78 .+-. 2 98 .+-.
3~ 96 .+-. 6 2 104 .+-. 4 73 .+-. 3 95.English Pound.1 96 .+-. 1 3
104 .+-. 2 78 .+-. 4 97 .+-. 3 97 .+-. 4 4 100 .+-. 2 74 .+-. 10 93
.+-. 4 96 .+-. 4 7 108 .+-. 5 72 .+-. 4 96 .+-. 2 94 .+-. 2 9 102
.+-. 3 66 .+-. 3 92 .+-. 3 93 .+-. 2 12 101 .+-. 2 66 .+-. 1 89
.+-. 2 92 .+-. 5
Each data point represents the mean.+-.relative standard deviation
of three individual samples taken from three separate vials.
EXAMPLE 4
Preparation of Reservoirs
Release Rate Profiles
[0138] Titanium reservoir systems of implantable drug delivery
devices (as disclosed in U.S. patent application Ser. No.
08/595,761, filed Feb. 2, 1996 (which was converted by petition to
U.S. Provisional Patent Application Ser. No. 60/122,056 on Jan. 21,
1997), incorporated herein by reference) were each assembled with
an osmotic engine, piston, and rate controlling membrane (i.e., a
semipermeable plug). The reservoirs were filled with the
appropriate amount of viscous vehicle formulation and capped with a
flow plug (i.e., a back-diffusion regulating outlet). The systems
were placed in a water bath at 37.degree. C., and allowed to
release formulation for an extended period of time. Released
material was sampled twice per week. Assays for released material
were completed using reverse phase HPLC. The resulting
concentrations of beneficial agent for each system were converted
to released amount per day. The beneficial agent was found to have
a zero order release from the implantable drug delivery device. As
shown in FIGS. 3 through 8.
EXAMPLE 5
Stability of hGH in Non-Aqueous Viscous Vehicle Formulations
[0139] Formulations of 10% w/w hGH in vehicle were prepared as
described above and placed in vials. The formulations were
subjected to accelerated aging by storing them at elevated
temperatures and times shown in the below table in a controlled
temperature oven.
TABLE-US-00007 TABLE 7 % LS Vehicle Time (hrs) Temperature % LS by
SEC by RP-HPLC Pluronic 105 0 50.degree. C. 98 .+-. 3 101 .+-. 3
Pluronic 105 1 50.degree. C. 98 .+-. 3 101 .+-. 4 Pluronic 105 2
so0c 100 .+-. 1 102 .+-. 3 Pluronic 105 4 50.degree. C. 101 .+-. 3
105 .+-. 3 GML/LL/PVP 0 65.degree. C. 99 .+-. 3 101 .+-. 3
GML/LL/PVP 1 65.degree. C. 93 .+-. 6 97 .+-. 6 GML/LL/PVP 2
65.degree. C. 91 .+-. 5 95 .+-. 5 GML/LL/PVP 4 65.degree. C. 95
.+-. 3 98 .+-. 3
Each data point represents the mean.+-.relative standard deviation
of three individual samples taken from three separate vials.
[0140] Results, presented in the following table, demonstrate that
these formulations were able to maintain the stability of the hGH
in each case. In each case, at least 70% hGH was retained.
TABLE-US-00008 TABLE 8 RECOVERY OF hGH FROM NONAQUEOUS SUSPENSIONS
Vehicle % LS by RP-HPLC % LS by Size-exclusion HPLC PVP/PEG 400 99
.+-. 3% 88 .+-. 6% GML/LL/PVP 99 .+-. 2% 92 .+-. 2% Pluronic 105 89
.+-. 7% 87 .+-. 7%
Each data point represents the mean .+-.relative standard deviation
of three individual samples taken from three separate vials.
% LS or % label strength=(measured protein content+theoretical
protein content).times.100%
[0141] Modification of the above-described modes of carrying out
various embodiments of this invention will be apparent to those of
skill in the art following the teachings of this invention as set
forth herein. The examples described above are not limiting, but
are merely exemplary of this invention, the scope of which is
defined by the following claims.
* * * * *